Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ACTR087 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ACTR087, in combination with rituximab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ACTR087 | BIOLOGICAL | - |
| rituximab | BIOLOGICAL | - |
Inclusion Criteria: * Signed written informed consent obtained prior to study procedures * Histologically-confirmed relapsed or refractory CD20+ B-cell lymphoma of one of the following types, with documented disease progression or recurrence following the immediate prior therapy: * DLBCL, regard...
Top 20 of 70 competitors
ACTR087 is an investigational monoclonal antibody being studied for the treatment of lymphoma, specifically relapsed or refractory B-cell lymphoma. It is being developed by Cogent Biosciences, Inc. and has been evaluated in a Phase 1 clinical trial. It is not approved for commercial use.
ACTR087 targets BCMA, a protein expressed on certain B cells. By binding to BCMA, the antibody is designed to direct immune activity toward B-cell lymphoma cells. BCMA is a protein target, and the drug is classified as a monoclonal antibody in the oncology therapeutic area.
ACTR087 is being developed by Cogent Biosciences, Inc., which trades under the ticker COGT. The company sponsored the Phase 1 study of the antibody in patients with relapsed or refractory B-cell lymphoma in the United States.
ACTR087 is in Phase 1 development. It is an investigational monoclonal antibody and has not been approved by the FDA. The Phase 1 trial evaluating ACTR087 in relapsed or refractory B-cell lymphoma has been completed.
ACTR087 has been evaluated in one clinical trial, NCT02776813, titled Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma. This Phase 1 trial enrolled 34 participants in the United States and is completed. It was an uncontrolled study without randomization or blinding.
Yes. The Phase 1 trial of ACTR087, NCT02776813, was biomarker selected, meaning participants were chosen based on a specific biological marker. The study enrolled 34 adults aged 18 years and older with relapsed or refractory B-cell lymphoma and was conducted in the United States.